focus -WSS

focus

author：knowledge 2025-10-01 15:31:35 - browse：7371

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Most antidepressants don't work on kids, teens, study finds

focus

WSS

Black vets could get higher VA benefits if race not used in lung test

Adults seen as increasingly susceptible to measles

AI for drug discovery: Experts on separating hype from reality

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Warren pushes Witty on UnitedHealth's control over physicians

Chemotherapy before breast cancer surgery might fuel metastasis

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Empower primary care with adequate payments and technology

Walensky prepares to leave CDC — and Congress — behind

‘Oppenheimer’ and the risks of AI in health care

New air purifier tech could be key to improving indoor air quality

Is it ever OK for doctors to lie to their patients?

Cancer drug shortages should be causing more outrage

Warren pushes Witty on UnitedHealth's control over physicians

Alkermes shareholders re

Class action alleges UnitedHealth concealed DOJ probe

hotspot

Lawsuit alleges UnitedHealth Group unit illegally denied claims

New safety details link Apellis eye drug to rare cases of blindness

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

What to expect as Trump is arraigned on his Jan 6. indictment

Sepsis can kill a child within hours. Here's how hospitals are fighting back

What to expect as Trump is arraigned on his Jan 6. indictment

explore

Wikipedia

focus

entertainment